Finally, in a mouse model of metastatic RCC, blockade of the IL34-CSF1R axis with the Food and Drug Administration (FDA)-approved drug pexidartinib prevented MD-TAMs accumulation in the TME and improved the response to sunitinib or anti-PD1 therapy. This evidence concerns the gene IL34 and renal cell carcinoma.